Dalhousie University Launches Clinical Trial in Oral Cancer Prevention
Researchers from Dalhousie University’s Faculty of Dentistry have launched a clinical trial to establish whether Metformin, a drug frequently used to treat type 2 diabetes, could be effective in the prevention of oral cancer.
In this video discussion, Dr. Leigha Rock, Assistant Professor at Dalhousie’s Faculty of Dentistry, gives some background behind the trial and highlights the positive impact it could have on patients with premalignant lesions.
“This is a trial to see if we can prevent the malignant transformation of oral pre-malignant lesions to full-blown cancer.” Dr. Leigha Rock
The trial is a collaboration between 10 sites across North America. Dr. Rock wishes to acknowledge the following colleagues for their contributions to the study:
-
-
- Dr. Miriam Rosin, BC Cancer
- Dr. Denise Laronde, BC Cancer/University of British Columbia
- Dr. Sherry Chow, Lead Academic Organization Principal Investigator, University of Arizona,
- Dr. Scott Lippman and Dr. Silvio Gutkind, Protocol Principal Investigator, University of California, San Diego Moores Cancer Center
- Dr. Eva Szabo, Scientific Lead and Medical Monitor, NCI/Division of Cancer Prevention
- Dr. Lisa Johnson, oral pathology/oral medicine specialist, Dalhousie University
- Dr. Chad Robertson, oral and maxillofacial surgeon, Dalhousie University
-
Helpful links:
